Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Product Safety in Pediatric Patients >3 to 17 Years of Age Requiring Long-term Parenteral Nutrition

A Randomized, Single-blind, Trial of Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Manganese Safety in Pediatric Patients Requiring Long-term Parenteral Nutrition

Tralement versus a fixed-dose trace element combination product of zinc, copper, and selenious acid to evaluate product safety in pediatric patients >3 to 17 years of age requiring long-term parenteral nutrition.

Study Overview

• Status: Not yet recruiting
• Conditions: Manganese Safety in Pediatric Patients
• Intervention / Treatment: Drug: Tralement; Drug: Fixed-dose trace element combination product of zinc, copper, and selenious acid

Detailed Description

A Phase IV, multi-center, randomized single-blind trial to evaluate the safety profile of Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid in pediatric patients who are expected to require at least six-months of home parenteral nutrition.

This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.

Eligible participants who satisfy the inclusion requirements and no exclusion criteria will be consented to participate in this study and enter the screening study phase.

The screening evaluation will be conducted within 5 days of the dose administration of study drug. Study participants meeting entry criteria of normal brain MRI and laboratory manganese concentrations (whole blood/plasma/serum/RBC) will begin study drug on Day 1.

Participants will undergo 2 additional post-baseline brain MRI scans at Months 3 and 6 and have either 2 (3.5-<7 years of age) and 4 (7-16 years of age) separate neuropsychological tests at Day 1, Month 3, and Month 6. Additional clinical monitoring including safety and laboratory assessments will occur during the 6-month opt-in extension study.

All patients in each assigned trace element parenteral nutrition group will have parenteral nutrition formulations evaluated for manganese content at Day 1, Month 1, Month 3, and Month 6.

• Study Type: Interventional
• Enrollment (Estimated): 80
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Mark Falone, MD; Phone Number: 631-816-8908; Email: mfalone@americanregent.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years to 17 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Pediatric (≥3 to 17 years of age) participants weighing >10 kg with assent to participation and his/her parent or legal guardian is willing and able to sign the informed consent approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC).
• Male and female participants who are new users to home parenteral nutrition as a source of trace elements when oral or enteral nutrition is not possible, insufficient, or, contraindicated.
• Anticipated duration of home parenteral nutrition use is 6 months or greater.
• A normal baseline brain MRI scan.
• A normal blood manganese concentration.
• Ability to undergo additional 2 brain MRI scans over the six-month study period (Sedation, if appropriate, to be determined by the Principal Investigator's study site, institutional review board recommendations, and parent/guardian assent).
• Definitive contraception for females of reproductive age.

Exclusion Criteria:

• Prior parenteral nutrition therapy.
• Hypersensitivity or allergy to zinc or copper.
• Baseline ferritin ≥300 ng/mL or below 100 ng/mL.
• Baseline Transferrin Saturation (TSAT) ≥45% or below 20%.
• Prior or current cholestatic liver disease defined as a clinical condition associated with decrease in bile flow due to impaired secretion by hepatocytes or to obstruction of bile flow through intra-or extrahepatic bile ducts.
• Liver function studies with transaminases greater than two-fold normal or total bilirubin >2 mg/dL.
• Brain MRI exclusion criteria: MRI-unsafe metal implants, claustrophobia.
• Known excess environmental exposure to manganese.
• Less than 1-year expected survival, as anticipated by their primary provider.
• Current participation in another clinical trial.
• Females in pregnant state.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Tralement; This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of long-term home parenteral nutrition requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.	Drug: Tralement; Tralement with Manganese
Active Comparator: a fixed-dose trace element combination product of zinc, copper, and selenious acid; This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of long-term home parenteral nutrition requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.	Drug: Fixed-dose trace element combination product of zinc, copper, and selenious acid; Tralement without Manganese

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess efficacy of brain deposition of manganese in Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid.	Change from baseline in basal ganglia index (BG-index) as determined by T1-weighted brain MRI images	Six months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the efficacy of Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid.	Change from baseline in blood (plasma/serum/RBC) manganese levels	Six months
To assess the safety of Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid	• Change from baseline in BG-index and pallidal index as determined by T1-weighted brain MRI images	Six months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess efficacy of Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid for the subset of participants who are eligible to, and consent to, the extension study.	• Whole blood and plasma/serum/RBC manganese levels and other serum trace element levels	12 months
To assess the safety of Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid for the subset of participants who are eligible to, and consent to, the extension study.	• Change from baseline in BG-index and pallidal index as determined by T1-weighted brain MRI images	12 months

Collaborators and Investigators

• Sponsor: American Regent, Inc.

Study record dates

Study Major Dates

• Study Start (Estimated): September 30, 2023
• Primary Completion (Estimated): October 31, 2025
• Study Completion (Estimated): December 4, 2026

Study Registration Dates

• First Submitted: December 13, 2022
• First Submitted That Met QC Criteria: December 22, 2022
• First Posted (Actual): January 10, 2023

Study Record Updates

• Last Update Posted (Actual): August 24, 2023
• Last Update Submitted That Met QC Criteria: August 23, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Copper; Micronutrients; Trace Elements; Selenious Acid
• Other Study ID Numbers: TE20002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No